| Literature DB >> 31445883 |
Ben Pode-Shakked1, Gali Heimer2, Thierry Vilboux3, Dina Marek-Yagel4, Bruria Ben-Zeev5, Mariska Davids6, Carlos R Ferreira7, Amit Mary Philosoph8, Alvit Veber8, Naomi Pode-Shakked9, Gili Kenet10, Michalle Soudack11, Chen Hoffmann12, Helly Vernitsky13, Marina Safaniev13, Maya Lodzki14, Avishay Lahad15, Dror S Shouval16, Dana Levinkopf17, Batia Weiss16, Assaf Arie Barg10, Ayman Daka17, Ninette Amariglio18, May Christine V Malicdan19, William A Gahl20, Yair Anikster21.
Abstract
Defects of the glycosylphosphatidylinositol (GPI) biosynthesis pathway constitute an emerging subgroup of congenital disorders of glycosylation with heterogeneous phenotypes. A mutation in the promoter of PIGM, resulting in a syndrome with portal vein thrombosis and persistent absence seizures, was previously described in three patients. We now report four additional patients in two unrelated families, with further clinical, biochemical and molecular delineation of this unique entity. We also describe the first prenatal diagnosis of PIGM deficiency, allowing characterization of the natural history of the disease from birth. The patients described herein expand the phenotypic spectrum of PIGM deficiency to include macrocephaly and infantile-onset cerebrovascular thrombotic events. Finally, we offer insights regarding targeted treatment of this rare disorder with sodium phenylbutyrate.Entities:
Keywords: Absence seizures; Congenital disorders of glycosylation; GPI; Glycosylphosphatidylinositol deficiency; PIGM; Portal vein thrombosis
Mesh:
Substances:
Year: 2019 PMID: 31445883 DOI: 10.1016/j.ymgme.2019.08.003
Source DB: PubMed Journal: Mol Genet Metab ISSN: 1096-7192 Impact factor: 4.797